A Biotech Comeback Story with Real Blood in the Game

In partnership with

This Technology Makes Every City a Potential Surf Destination

Topgolf revolutionized golf by turning it into a social, tech-driven game for anyone. And they’ve made billions in annual revenue doing it. Surf Lakes is applying that same model to surfing. Their patented tech creates 2,000 ocean-quality rides per hour, anywhere in the world, across all skill levels.

Surf tourism is a $65B global industry, yet fewer than 1% of people live near real waves. Licenses sold across the U.S. and Australia, with plans for a first commercial park in the works.

3x world champ Tom Curren and surf icon Mark Occhilupo have joined as ambassadors and shareholders. Even actor Chris Hemsworth has praised Surf Lakes.

You have until October 30th at 11:59 PM PT to invest in Surf Lakes.

Invest In Surf Lakes

_{This is a paid advertisement for Surf Lakes’ Regulation CF offering. Please read the offering circular at https://invest.surflakes.com}

30‑Second Take

Disc Medicine has broken out of its late-summer slump and is energetically climbing through the price charts thanks to renewed optimism around its rare blood disorder treatments.

With multiple mid-stage clinical readouts expected in the coming months, the stock’s momentum feels more grounded in fundamentals than hype. 

Yes, biotech always carries risk from data delays, trial results, or FDA curveballs, but Disc’s strong cash position and differentiated pipeline make it one of the few small-cap biotechs that’s actually funded through its next milestones. 

This is a setup that looks more interesting by the day: enough catalysts ahead to keep traders engaged, and enough science behind it to justify your curiosity.

Trade Setup

Timeframe: Long-term

Edge Type: Pipeline-driven growth

If you’re the kind of investor who doesn’t mind a bit of patience in exchange for real potential, this one’s worth a look.

Disc Medicine isn’t a quick flip. It's a classic biotech story where the real action unfolds over quarters, not weeks.

The company's niche focus on rare blood disorders gives it an edge in a space big pharma tends to overlook.

With enough cash to keep the lights on through 2026, there's time for the science to do the talking.

Think of it as planting a seed. You won't get instant shade, but give it time, and it could grow into something substantial.

Snapshot Table

Chart

1-month trading summary: Disc Medicine has been on a tear — up 46.75% over the past month — as investors pile back into promising small-cap biotechs.

The rally kicked off after upbeat commentary around its upcoming trial data and has held strong, with IRON now trading well above key moving averages and attracting noticeably higher volume.

It’s the kind of price action that gets traders leaning in and long-term holders quietly nodding, because when a stock climbs nearly 50% in a month without a single hype-driven headline, it usually means something deeper is stirring beneath the surface.

Bull Case 

Carving out a bull case with a science-first approach: Disc Medicine is carving out its place in hematology with a science-first approach that’s finally catching attention.

The company’s pipeline targets rare and severe blood disorders — areas where treatment options are scarce and breakthrough therapies can be transformative.

Its lead programs, including bitopertin and DISC-0974, aim to treat conditions like erythropoietic porphyria and anemia of inflammation, both high-need markets with limited competition.

What gives Disc an edge is its disciplined execution and cash runway that stretches comfortably into 2026, removing the usual biotech funding overhang.

A stacked pipeline: IRON’s lead drug, bitopertin, is on track for an NDA submission this month (October 2025) for erythropoietic protoporphyria (EPP) under the accelerated approval pathway, a big milestone backed by a successful pre-NDA meeting with regulators.

That alone might be enough to get you leaning in, but there’s more brewing. 

Disc expects initial Phase 2 data for DISC-0974 in anemia of myelofibrosis (MF) and additional Phase 1b results in non-dialysis-dependent chronic kidney disease (NDD-CKD) before the end of Q4 2025, while the Phase 2 DISC-3405 study in polycythemia vera (PV) just kicked off.

The first data in those trials is due in 2026. What we’re dealing with here is a stacked pipeline calendar that gives multiple shots on goal within months — a rare setup in the biotech world.

Price targets: These range from a low of $85.00 to a high of $153.00. 

Technical momentum powered by science: Momentum has turned decisively in Disc’s favour.

The stock is now trading well above its 20-, 50-, and 200-day moving averages, signalling a strong technical uptrend backed by conviction rather than hype.

Trading volume has also picked up noticeably since mid-September, confirming that new money is flowing in.

For a biotech that spent much of the year drifting sideways, IRON's chart finally looks like its science is being taken seriously.

Bear Case 

There are no guarantees in biotech: This is biotech, and nothing's guaranteed.

A setback in trial data or regulatory feedback could easily stall momentum and send shares sliding.

Despite substantial funding, Disc is still pre-revenue, so every catalyst cuts both ways: significant upside if results impress, but painful drawdowns if they don't.

A crowded corner: Disc operates in a crowded but opportunity-rich corner of hematology.

Rivals like GSK and Pfizer have larger hematology portfolios, while Acceleron’s legacy programs (now under Merck) set the benchmark for innovation in blood disorder therapeutics.

Smaller players such as Protagonist Therapeutics have also chased similar anemia pathways. Disc’s data will need to stay sharp if it is to compete.

Navigating sector headwinds: Biotech sentiment has improved since early 2025, but it’s still fragile.

Rising rates and a tighter funding environment mean investors remain selective, favouring proven platforms over early-stage stories.

Regulatory timelines can also shift without warning, and with the FDA under pressure to tighten accelerated approvals, even good science can face longer waits.

Chasing momentum: Biotech sentiment can turn herd-like fast.

With Disc’s stock up nearly 50% in a month, short-term traders could start piling in, chasing momentum rather than the science.

Quick Checklist 

✅ Thesis still valid after today’s close
✅ Volume confirms move above key levels
✅ Catalyst date double-checked (October 19, 2025)

Deep‑Dive Links

• Q2 2025 Earnings 

• Analyst Ratings and Price Targets

• Short Interest Data

• Company Profile and Investor Relations

That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!

Best Regards,
—Noah Zelvis
Everyday Alpha